Fig. 3: Real-world progression-free survival in patients with left-sided, RAS/BRAF wild-type and MSI-H not detected mCRC by ERBB2 amplification status. | British Journal of Cancer

Fig. 3: Real-world progression-free survival in patients with left-sided, RAS/BRAF wild-type and MSI-H not detected mCRC by ERBB2 amplification status.

From: Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy

Fig. 3

Kaplan–Meier survival curves comparing rwPFS in all patients by ERBB2 amplification, and among patients with ERBB2 amp+, and in patients treated with doublet + anti-EGFR antibody vs doublet + bevacizumab. rwPFS real-world progression-free survival, HR hazard ratio, CI confidence interval, MSI-H microsatellite instability-high.

Back to article page